Determinants of gastro-protective drugs co-prescription during treatment with nonselective NSAIDs: a prospective survey of 2197 patients recruited in primary care

Osteoarthritis and Cartilage

Volumn 14, Issue 7, 2006, Pages 625-630

  Rabenda, V ^a,b   Burlet, N ^a,b   Belaiche, J ^c   Raeman, F ^d   Richy, F ^a,b   Reginster, J Y ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b WHO Collaborating Center for Public Health Aspects of Rheumatic Diseases   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d Jan Palfijn Hospital   (Belgium)

Author keywords

Adverse events; Co prescription; Gastro protective drugs; Nonsteroidal anti inflammatory drugs; Osteoarthritis; Treatment

Indexed keywords

ANTACID AGENT; DICLOFENAC; DOMPERIDONE; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; IBUPROFEN; LANSOPRAZOLE; MELOXICAM; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PIROXICAM; RANITIDINE;

ADULT; AGE; AGED; ANAMNESIS; ARTICLE; BONE PAIN; CELL PROTECTION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EPIGASTRIC PAIN; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; HEALTH SURVEY; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; OSTEOARTHRITIS; PREDICTION; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STANDARDIZATION; TREATMENT DURATION; VOMITING;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BELGIUM; FEMALE; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; POLYPHARMACY; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 33744902100     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2006.01.002     Document Type: Article

References (31)

1. Reginster J.Y. The prevalence and burden of arthritis. Rheumatology 41 Suppl 1 (2002) 3-6
2. Report of a WHO Scientific Group. The burden of musculoskeletal conditions at the start of the new millennium. WHO Technical Report Series 919. Geneva: World Health Organization, 2003; 1-218.
3. Macdonald T.M. Epidemiology and pharmacoeconomic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity. Rheumatology (Oxford) 39 Suppl 2 (2000) 13-20
4. Spiegel B.M., Targownik L., Dulai G.S., and Gralnek I.M. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 138 (2003) 795-806
5. Larkai E.N., Smith J.L., Lidsky M.D., and Graham D.Y. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 82 (1987) 1153-1158
6. Lapane K.L., Spooner J.J., and Pettitt D. The effect of nonsteroidal anti-inflammatory drugs on the use of gastroprotective medication in people with arthritis. Am J Manag Care 7 (2001) 402-408
7. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2002) 1520-1528
8. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
9. Simon L.S., Hatoum H.T., Bittman R.M., Archambault W.T., and Polisson R.P. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Med 28 (1996) 204-210
10. Graham D.Y., Agrawal N.M., and Roth S.H. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 2 (1988) 1277-1280
11. Wolfe M.M., Lichtenstein D.R., and Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340 (1999) 1888-1899
12. La Corte R., Caselli M., Castellino G., Bajocchi G., and Trotta F. Prophylaxis and treatment of NSAID-induced gastroduodenal disorders. Drug Saf 20 (1999) 527-543
13. van Dijk K.N., ter Huurne K., de Vries C.S., van den Berg P.B., Brouwers J.R., and de Jong-van den Berg L.T. Prescribing of gastroprotective drugs among elderly NSAID users in the Netherlands. Pharm World Sci 24 (2002) 100-103
14. Belaiche J., Burette A., De Vos M., Louis E., Huybrechts M., and Deltenre M. Belgian Study Group of NSAID-GI Complications. Observational survey of NSAID-related upper gastro-intestinal adverse events in Belgium. Acta Gastroenterol Belg 55 (2002) 65-73
15. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 120 (2001) 594-606
16. Moore R.A., and Phillips C.J. Cost of NSAID adverse effects to the UK National Health Service. J Med Econ 2 (1999) 45-55
17. Solomon D.H., Glynn R.J., Bohn R., Levin R., and Avorn J. The hidden cost of nonselective nonsteroidal anti-inflammatory drugs in older patients. J Rheumatol 30 (2003) 792-798
18. Wiklund I. Quality of life in arthritis patients using nonsteroidal anti-inflammatory drugs. Can J Gastroenterol 13 (1999) 129-133
19. Cunningham L.S., and Kelsey J.L. Epidemiology of musculoskeletal impairments and associated disability. Am J Public Health 74 (1984) 574-579
20. Langman M., Kahler K.H., Kong S.X., Zhang Q., Finch E., Bentkover J.D., et al. Drug switching patterns among patients taking non-steroidal anti-inflammatory drugs: a retrospective cohort study of a general practitioners database in the United Kingdom. Pharmacoepidemiol Drug Saf 10 (2001) 517-524
21. Martin R.M., Biswas P., and Mann R.D. The incidence of adverse events and the risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study. Br J Clin Pharmacol 50 (2000) 35-42
22. Saturno P.J., Palmer R.H., and Gascon J.J. Physician attitudes, self-estimated performance and actual compliance with locally peer-defined quality evaluation criteria. Int J Qual Health Care 11 (1999) 487-496
23. Gabriel S.E., Jaakkimainen L., and Bombardier C.S. Risk for serious gastrointestinal complications related to the use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 115 (1991) 787-796
24. Hansen J.M., Hallas J., Lauritsen J.M., and Bytzer P. Non-steroidal anti-inflammatory drugs and complications: a risk factor analysis for clinical decision-making. Scand J Gastroenterol 31 (1996) 126-130
25. Richy F., Bruyère O., Ethgen O., Rabenda V., Bouvenot G., Audran M., et al. Time-dependent risk of gastrointestinal complications induced by NSAIDS use: a consensus statement using meta-analytic approach. Ann Rheum Dis 63 7 (2004) 759-766
26. Pettitt D., Goldstein J.L., McGuire A., Schwartz J.S., Burke T., and Maniadakis N. Overview of the arthritis cost consequence evaluation system (ACCES): a pharmacoeconomic model for celecoxib. Rheumatology (Oxford) 39 Suppl 2 (2000) 33-42
27. MacDonald T.M., Morant S.V., Robinson G.C., Shield M.J., McGilchrist M.M., Muray F.E., et al. Association of upper gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 315 (1997) 1333-1337
28. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 105 (1998) 31S-38S
29. Clinard F., Bardou M., Sgro C., Lefevre N., Raphael F., Paille F., et al. Non-steroidal anti-inflammatory and cytoprotective drug co-prescription in general practice. A general practitioner-based survey in France. Eur J Clin Pharmacol 57 (2001) 737-743
30. Schnitzer T.J., Kong S.X., Mavros P.P., Straus W.L., and Watson D.J. Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: analysis of a large United States claims database. Clin Ther 23 (2001) 1984-1998
31. Sturkenboom M.C., Romano F., Simon G., Correa-Leite M.L., Villa M., Nicolosi A., et al. The iatrogenic costs of NSAID therapy: a population study. Arthritis Rheum 47 (2002) 132-140